Effect of Prereperfusion Dapagliflozin Loading on Infarct Size, Mitochondrial Function, and Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial.
Suwannasom Pannipa P, Apaijai Nattayaporn N, Noparatkailas Nabhat N, Leemasawat Krit K et al.
Sodium-glucose cotransporter-2 inhibitors demonstrate cardioprotective effects in preclinical ischemia-reperfusion models, potentially mediated by mitochondrial modulation, but their benefit in acute ST-segment elevation myocardial infarction remains uncertain. In this randomized, double-blind, placebo-controlled trial, 60 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention were assigned to dapagliflozin (20 mg prereperfusion followed by 10 mg daily) or placebo for 12 weeks. The primary endpoint was enzymatic infarct size assessed by the 72-hour area under the curve of high-sensitivity cardiac troponin I. Dapagliflozin did not reduce infarct size compared with placebo (adjusted difference: -0.89 × 106 arbitrary unit; P = 0.47). Although mitochondrial respiratory capacity increases transiently at 2 weeks, this effect was not sustained. Left ventricular function improved similarly in both groups, and cardiac magnetic resonance-derived infarct size did not differ significantly. Prereperfusion dapagliflozin was not associated with reduced infarct size despite transient mitochondrial modulation. The neutral findings should be interpreted in the context of the brief drug-to-wire interval and the limited statistical power of this pilot trial.